Trial Profile

52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese/Overweight Men With T2DM/Prediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 16 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Testosterone undecanoate (Primary)
Indications Hypogonadism; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms Test2Func

12 Mar 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2028.
12 Mar 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2028.
08 Apr 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com